share_log

Piper Sandler Maintains Overweight on Century Therapeutics, Lowers Price Target to $4

Benzinga ·  Dec 30, 2024 09:19  · Ratings

Piper Sandler analyst Edward Tenthoff maintains Century Therapeutics (NASDAQ:IPSC) with a Overweight and lowers the price target from $12 to $4.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment